Managed entry agreements for pharmaceutical products in Middle East and North African countries
Objectives The first objective is to describe current managed entry agreement (MEA) activity in the Middle East and North African (MENA) region and the pharmaceutical decision makers’ perception and use of these agreements; The second objective is to describe the challenges as well as to reflect on...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | article |
| منشور في: |
2018
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/11500 https://doi.org/10.1016/j.vhri.2018.04.003 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S2212109918300980 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513488800448512 |
|---|---|
| author | Maskineh, Christiane |
| author2 | Nasser, Soumana C. |
| author2_role | author |
| author_facet | Maskineh, Christiane Nasser, Soumana C. |
| author_role | author |
| dc.creator.none.fl_str_mv | Maskineh, Christiane Nasser, Soumana C. |
| dc.date.none.fl_str_mv | 2018 2019-11-07T09:44:57Z 2019-11-07T09:44:57Z 2019-11-07 |
| dc.identifier.none.fl_str_mv | 2212-1102 http://hdl.handle.net/10725/11500 https://doi.org/10.1016/j.vhri.2018.04.003 Maskineh, C., & Nasser, S. C. (2018). Managed entry agreements for pharmaceutical products in Middle East and North African countries: payer and manufacturer experience and outlook. Value in health regional issues, 16, 33-38. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S2212109918300980 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Value in Health Regional Issues |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Managed entry agreements for pharmaceutical products in Middle East and North African countries payer and manufacturer experience and outlook |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Objectives The first objective is to describe current managed entry agreement (MEA) activity in the Middle East and North African (MENA) region and the pharmaceutical decision makers’ perception and use of these agreements; The second objective is to describe the challenges as well as to reflect on the uncertainty related to MEAs implementation and the future outlook for MEAs activities in the region. Study Design A prospective cross-sectional survey. Methods A questionnaire was sent to several pharmaceutical manufacturers and public officials involved in pricing and reimbursement of pharmaceuticals in the region. Results Of the 62% of total respondents, 25% were from the public sector, with the remainder from the pharmaceutical (pharma) industry. Only 42% of participants reported having MEAs running in their institutions, the majority representing Lebanon. All respondents reported the use of financial-based agreements, most referring to “discounted treatment” and, to a lesser extent, a “price volume agreement.” Financial-based agreements were reported as either the only type of MEA (71.4%) being used or as being used with outcomes-based agreements (28.6%). The majority of participants ranked challenges in identifying and measuring relevant data as well as the lack of expertise in assessing health economics data. The majority of respondents projected an increase in the use of MEAs to address budget impact while improving access to innovative care. Conclusions Few MENA countries are implementing MEAs, which could be due to lack of data infrastructure as well as a shortage of experts in health economics. Health care stakeholders continue to be optimistic regarding the potential of MEA implementation. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_8001e732cf16d48c1d6caaff87af512b |
| identifier_str_mv | 2212-1102 Maskineh, C., & Nasser, S. C. (2018). Managed entry agreements for pharmaceutical products in Middle East and North African countries: payer and manufacturer experience and outlook. Value in health regional issues, 16, 33-38. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/11500 |
| publishDate | 2018 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Managed entry agreements for pharmaceutical products in Middle East and North African countriespayer and manufacturer experience and outlookMaskineh, ChristianeNasser, Soumana C.Objectives The first objective is to describe current managed entry agreement (MEA) activity in the Middle East and North African (MENA) region and the pharmaceutical decision makers’ perception and use of these agreements; The second objective is to describe the challenges as well as to reflect on the uncertainty related to MEAs implementation and the future outlook for MEAs activities in the region. Study Design A prospective cross-sectional survey. Methods A questionnaire was sent to several pharmaceutical manufacturers and public officials involved in pricing and reimbursement of pharmaceuticals in the region. Results Of the 62% of total respondents, 25% were from the public sector, with the remainder from the pharmaceutical (pharma) industry. Only 42% of participants reported having MEAs running in their institutions, the majority representing Lebanon. All respondents reported the use of financial-based agreements, most referring to “discounted treatment” and, to a lesser extent, a “price volume agreement.” Financial-based agreements were reported as either the only type of MEA (71.4%) being used or as being used with outcomes-based agreements (28.6%). The majority of participants ranked challenges in identifying and measuring relevant data as well as the lack of expertise in assessing health economics data. The majority of respondents projected an increase in the use of MEAs to address budget impact while improving access to innovative care. Conclusions Few MENA countries are implementing MEAs, which could be due to lack of data infrastructure as well as a shortage of experts in health economics. Health care stakeholders continue to be optimistic regarding the potential of MEA implementation.PublishedN/A2019-11-07T09:44:57Z2019-11-07T09:44:57Z20182019-11-07Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2212-1102http://hdl.handle.net/10725/11500https://doi.org/10.1016/j.vhri.2018.04.003Maskineh, C., & Nasser, S. C. (2018). Managed entry agreements for pharmaceutical products in Middle East and North African countries: payer and manufacturer experience and outlook. Value in health regional issues, 16, 33-38.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://www.sciencedirect.com/science/article/pii/S2212109918300980enValue in Health Regional Issuesinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/115002021-03-19T10:47:38Z |
| spellingShingle | Managed entry agreements for pharmaceutical products in Middle East and North African countries Maskineh, Christiane |
| status_str | publishedVersion |
| title | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| title_full | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| title_fullStr | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| title_full_unstemmed | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| title_short | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| title_sort | Managed entry agreements for pharmaceutical products in Middle East and North African countries |
| url | http://hdl.handle.net/10725/11500 https://doi.org/10.1016/j.vhri.2018.04.003 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S2212109918300980 |